Overview

Study to Evaluate the Long-term Safety of Etrolizumab in Participants With Moderate to Severe Ulcerative Colitis

Status:
Completed
Trial end date:
2016-08-07
Target enrollment:
Participant gender:
Summary
This study is an open-label extension (OLE) trial to evaluate the safety and tolerability of etrolizumab in participants with moderate to severe ulcerative colitis (UC) who were enrolled in the Phase II Study ABS4986g (NCT01336465) and meet the eligibility criteria for entry in the OLE study.
Phase:
Phase 2
Details
Lead Sponsor:
Genentech, Inc.
Treatments:
Etrolizumab